Identification of cancer-stem cell antigens and development of CTL-mediated cancer immunotherapy
-
- MIYAMOTO Sho
- Department of Pathology, Sapporo Medical University School of Medicine Department of Oral Surgery, Sapporo Medical University School of Medicine
-
- KANASEKI Takayuki
- Department of Pathology, Sapporo Medical University School of Medicine
-
- HIROHASHI Yoshihiko
- Department of Pathology, Sapporo Medical University School of Medicine
-
- TSUKAHARA Tomohide
- Department of Pathology, Sapporo Medical University School of Medicine
-
- KIKUCHI Yasuhiro
- Department of Pathology, Sapporo Medical University School of Medicine
-
- SATO Noriyuki
- Department of Pathology, Sapporo Medical University School of Medicine
-
- TORIGOE Toshihiko
- Department of Pathology, Sapporo Medical University School of Medicine
Bibliographic Information
- Other Title
-
- がん幹細胞の単離と免疫治療に向けた標的抗原の同定
Search this article
Abstract
<p> Cancer-stem cells (or cancer-stem like cells, CSC) play an indispensable role in tumor initiation or tumor development in vivo. However, CSCs are resistant to conventional therapies including chemo/radiotherapy and a certain molecularly-targeted therapy, thereby are responsible for tumor relapse or metastasis in clinical settings. In this review, we focus on cytotoxic T-cell mediated immune responses against CSCs and discuss a challenge of targeting CSCs as well as the development of CSC-based cancer immunotherapy, which is an emerging and promising strategy toward a complete cure of quite a few types of cancers.</p>
Journal
-
- Japanese Journal of Clinical Immunology
-
Japanese Journal of Clinical Immunology 40 (1), 40-47, 2017
The Japan Society for Clinical Immunology